Carla I. Falkson - Concepedia

Author

Carla I. Falkson

University of Alabama at Birmingham ORCID

Also Known As

Arteaga, Carlos L., C Falkson, C I Falkson, C. Falkson, C. I. Falkson, C.I. Falkson, Carla Falkson, Carla I Falkson, Carla I. Falkson, Carla Isadora Falkson

162

Publications

Citations

H-Index

Concepts

All Affiliations

University of Alabama at Birmingham University of Pretoria Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center University of North Carolina at Chapel Hill

About

Carla I. Falkson is an author at University of Alabama at Birmingham specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	34	2.1K
2	Health Sciences	9	9	322
3	Cell Biology	4	4	113
4	Nursing	1	1	69
5	Endocrinology	1	1	13

Carla I. Falkson

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. DJ Slamon, W. Eiermann, Nicholas J. Robert, Cancer Research Breast OncologyOncologyCyclophosphamide FollowedBreast Cancer PatientsCancer Management	2009	554
Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells Shaohua Yu, Cunren Liu, Kaihong Su, The Journal of Immunology	2007	419
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial Jean-Marc Nabholtz, Carla I. Falkson, J. Szántó, Journal of Clinical Oncology	2003	383
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. Carla I. Falkson, Joseph Ibrahim, John M. Kirkwood, Journal of Clinical Oncology	1998	304
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Milan Radovich, Guanglong Jiang, Bradley A. Hancock, JAMA Oncology	2020	292
Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node–Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189 Jean F. Simpson, Robert J. Gray, Lynn G. Dressler, Journal of Clinical Oncology	2000	206
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. Carla I. Falkson, Geoffrey Falkson, H. C. Falkson Journal of Clinical Oncology OncologyMetastatic Malignant MelanomaMedicineIfn ToxicityMelanoma	1991	197
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial Alexander Paterson, Stewart Anderson, Barry C. Lembersky, The Lancet Oncology Surgical OncologyOncologyBreast OncologyRandomised TrialPharmacology	2012	191
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, JAMA Oncology	2018	162
Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006 Nalini Sathiakumar, Elizabeth Delzell, Michael A. Morrisey, Breast Cancer Research and Treatment Breast OncologyCancer EpidemiologyMedicineEpidemiology Of CancerBreast Cancer	2011	131

Page 1